Viiv's Selzentry HIV combo fails PhIII, but disappointment mild
This article was originally published in Scrip
Executive Summary
A dual combination of Viiv Healthcare's anti-HIV-1 drug maraviroc (marketed as Selzentry/Celsentri) and darunavir/ritonavir has failed to show non-inferiority over a triple combination of emtricitabine, tenofovir and darunavir/ritonavir. But while the results are disappointing, they are not disastrous as the company has more important products approaching the market.